Jack Kaye Sells 1,993 Shares of uniQure (NASDAQ:QURE) Stock

uniQure N.V. (NASDAQ:QURE) Director Jack Kaye sold 1,993 shares of the firm’s stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $27.06, for a total value of $53,930.58. Following the completion of the sale, the director directly owned 25,996 shares of the company’s stock, valued at approximately $703,451.76. This trade represents a 7.12% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Jack Kaye also recently made the following trade(s):

• On Wednesday, June 3rd, Jack Kaye sold 2,645 shares of uniQure stock. The shares were sold at an average price of $30.01, for a total value of $79,376.45.

uniQure Stock Up 2.8%

Shares of QURE stock traded up $0.75 on Friday, reaching $27.57. 835,627 shares of the company’s stock traded hands, compared to its average volume of 2,601,234. uniQure N.V. has a 12-month low of $8.73 and a 12-month high of $71.50. The company has a debt-to-equity ratio of 0.33, a quick ratio of 10.40 and a current ratio of 10.40. The company has a market capitalization of $1.74 billion, a P/E ratio of -7.92 and a beta of 0.98. The business’s 50 day moving average price is $22.31 and its two-hundred day moving average price is $21.76.

uniQure (NASDAQ:QURE) last issued its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.03. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%.The business had revenue of $3.56 million for the quarter, compared to the consensus estimate of $5.21 million. On average, equities analysts forecast that uniQure N.V. will post -3.64 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the company. Royal Bank Of Canada upgraded uniQure from a “sector perform” rating to an “outperform” rating and lifted their price target for the company from $11.00 to $35.00 in a report on Monday, March 9th. Wolfe Research assumed coverage on uniQure in a report on Monday, February 23rd. They set a “peer perform” rating on the stock. Stifel Nicolaus set a $28.00 price target on uniQure in a report on Tuesday, May 5th. Sanford C. Bernstein lowered uniQure to a “market perform” rating in a report on Tuesday, March 3rd. Finally, Mizuho upgraded uniQure from a “neutral” rating to an “outperform” rating and increased their price objective for the stock from $12.00 to $35.00 in a report on Wednesday, March 11th. Ten research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $42.83.

Institutional Trading of uniQure

Several hedge funds and other institutional investors have recently modified their holdings of the company. Avoro Capital Advisors LLC raised its holdings in shares of uniQure by 38.4% during the fourth quarter. Avoro Capital Advisors LLC now owns 6,150,000 shares of the biotechnology company’s stock worth $147,170,000 after acquiring an additional 1,705,556 shares in the last quarter. Aberdeen Group plc raised its holdings in shares of uniQure by 25.1% during the fourth quarter. Aberdeen Group plc now owns 3,678,640 shares of the biotechnology company’s stock worth $88,030,000 after acquiring an additional 738,897 shares in the last quarter. State Street Corp raised its holdings in shares of uniQure by 123.8% during the fourth quarter. State Street Corp now owns 3,231,043 shares of the biotechnology company’s stock worth $77,319,000 after acquiring an additional 1,787,033 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in shares of uniQure by 155.3% during the fourth quarter. JPMorgan Chase & Co. now owns 2,934,626 shares of the biotechnology company’s stock worth $70,226,000 after acquiring an additional 1,785,275 shares in the last quarter. Finally, Orbimed Advisors LLC raised its holdings in shares of uniQure by 189.7% during the first quarter. Orbimed Advisors LLC now owns 2,136,149 shares of the biotechnology company’s stock worth $34,926,000 after acquiring an additional 1,398,749 shares in the last quarter. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.